Selvita signs contract with Rottapharm Madaus

For drug discovery services

Italian pharmaceutical firm Rottapharm Madaus and Selvita, a Polish biotechnology company, have signed a drug discovery services contract. The aim of the deal is to deliver to Monza-based Rottapharm a set of designed and synthesised compounds, which will have a therapeutic potential in an indicated area.

Rottapharm’s r&d is focused on therapeutic areas such as rheumatology, gynaecology, urology, gastroenterology, bronchopneumology, psychiatry and oncology.

Selvita Group provides integrated drug discovery projects; chemistry services; biology services; and advanced protein modelling solutions.

‘We are keen to take advantage of Selvita’s know-how to support the progression of our drug discovery pipeline,’ said Luigi Stasi, Rottapharm’s director of the Medicinal Chemistry Department.

‘This project is an immense chance for Selvita to show the great potential of our computational chemistry and chemistry departments,’ said Pawel Przewiezlikowski, chief executive of Selvius.

Companies